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Humans and swine are susceptible to influenza A viruses (IAVs) of hemagglutinin (HA) subtypes 
H1 and H3, which are widespread in both species. 
Human IAVs frequently are transmitted to swine, 
after which the HA surface protein generally under-
goes slower antigenic evolution (drift) in swine than 
in humans (1–3). Therefore, swine can be considered 
a reservoir for past human IAVs. Because antigenic 
drift variants of human IAVs replace each other over 
time, younger persons only have been exposed to 
more recent strains and human population immunity 
against older human IAVs gradually decreases (4). 
Consequently, human-origin swine IAVs (swIAVs) 
can be reintroduced into the human population after 
a certain period and cause a pandemic, as illustrated 
by the influenza A(H1N1)pdm09 virus (pH1N1) (5). 
The H1 of this swine-origin virus is related to the 
H1 of human seasonal H1N1 IAVs that circulated 
in 1918–1950. In 2009, only persons born before the 
1950s had cross-reactive antibodies against pH1N1, 
so a pandemic was possible (6,7).
The evolution of swIAVs is different from and 
more complex than that of human IAVs because of 
multiple introductions of human IAVs into swine 
and geographic separation of swine populations 
(8). H1 swIAV colloquial names indicate their ori-
gin and region of circulation. An improved classi-
fication system subdivides H1 swIAVs into 3 lin-
eages and 28 clades on the basis of H1 nucleotide 
sequence homology (9). The lineages are 1A, 1B, 
and 1C, with the number representing the subtype 
(H1) and the letter representing the lineage. Clades 
and subclades are indicated with 1–3 digits. Classi-
cal swine lineage 1A contains IAVs with the human 
1918 pandemic H1N1 virus as a common ancestor. 
Most clades are restricted to America and Asia, but 
pH1N1 viruses (1A.3.3.2) circulate in swine and hu-
mans worldwide. Human seasonal lineage 1B con-
tains swIAVs with an H1 derived from human sea-
sonal IAVs. These human-like H1 swIAVs emerged 
in Europe in the late 1980s and in North America in 
the early 2000s. Eurasian avian lineage 1C contains 
swIAVs that originated from avian IAVs. These 
avian-like swIAVs emerged in Europe in 1979 and 
spread to Asia in 1993 (10–13). Apart from antigenic 
evolution in the HA, IAVs also can evolve via ex-
change of gene segments with other IAVs of differ-
ent subtypes or clades infecting the same cell, called 
reassortment (14), which frequently occurs in pigs. 
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Most H1 influenza A viruses (IAVs) of swine are derived 
from past human viruses. As human population immu-
nity against these IAVs gradually decreases, the risk of 
reintroduction to humans increases. We examined 549 
serum samples from persons 0–97 years of age collect-
ed in Belgium during 2017–2018 for hemagglutination 
inhibiting and virus neutralizing antibodies against 7 ma-
jor H1 swine IAV (swIAV) clades and 3 human progeni-
tor IAVs. Seroprevalence (titers >40) rates were >50% 
for classical swine and European human-like swIAVs, 
>24% for North American human-like δ1a and Asian 
avian-like swIAVs, and <10% for North American hu-
man-like δ1b and European avian-like swIAVs, but rates 
were age-dependent. Antibody titers against human-like 
swIAVs and supposed human precursor IAVs correlated 
with correlation coefficients of 0.30–0.86. Our serologic 
findings suggest that European avian-like, clade 1C.2.1, 
and North American human-like δ1b, clade 1B.2.2.2, H1 
swIAVs pose the highest pandemic risk.
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A reassortant IAV with an antigenically novel HA 
and the capacity to infect and spread in humans 
could cause a pandemic.
Since 2010, 35 zoonotic infections with H1 swIA-
Vs were reported in North America and 10 in Europe 
(15–17; Parys et al., unpub. data). Human population 
immunity is a major factor determining the pandemic 
risk for swIAVs. Hemagglutination inhibiting (HI) 
and virus neutralizing (VN) antibodies in serum are 
accepted correlates of protection (18). Evaluating hu-
mans of different age groups for HI and VN antibody 
titers against a range of antigenically different swIA-
Vs might help clarify the public health risk.
In a previous seroprevalence study for H3 swIA-
Vs in humans from Luxembourg, we demonstrated 
a correlation with the nature of the swIAV and its 
relation to human IAVs on the one hand and the 
persons’ birth year on the other (19). A large com-
parative seroprevalence study for H1 swIAVs is 
lacking. Previous studies examined limited numbers 
of H1 swIAVs or samples or did not evaluate the 
relation between birth year and antibody responses 
(12,13,20–25). In addition, most studies were con-
ducted before or during the 2009 pandemic, but 
the circulation of pH1N1 viruses in humans likely 
changed the serologic profile against H1 swIAVs. 
We assessed prevalence and titers of protective anti-
bodies against all major H1 swIAV clades in various 
age groups in Belgium in 2017. We also examined 
the relation between antibodies against human-like 
swIAVs and their presumed human seasonal an-
cestor IAV. The results will help assess the public 
health risk for different H1 swIAVs.
Materials and Methods
Sample Collection
During August 2017–January 2018, a total of 549 
anonymized serum samples were collected from 
immunocompetent persons with unknown influ-
enza vaccination or infection history born during 
1920–2017 at Ghent University Hospital (Ghent, Bel-
gium). Samples included ≈6 per birth year with ≈1:1 
ratio between male and female patients. Exclusion 
criteria included active oncologic disease or hemato-
logic malignancies, immunosuppressive treatment, 
organ transplantation, admission to intensive care, 
and end-stage renal disease on dialysis treatment. 
This study was approved by the Commission for 
Medical Ethics of the Ghent University Hospital (ap-
proval no. 2017/0834).
Viruses
Samples were evaluated for antibodies against 
11 viruses representing 7 major H1 swIAV clades 
circulating in Europe, North America, and Asia; 2 hu-
man seasonal progenitor IAVs for European and North 
American human-like swIAVs; and 1 human seasonal 
IAV that circulated right before the pH1N1 virus (Ta-
ble 1). We used epidemiologic data (10–12) and the 
H1 classification system (9) to select major H1 swIAV 
clades. We selected test viruses on the basis of amino 
acid homology and antigenic relatedness to currently 
circulating swIAVs of each clade. We selected the hu-
man progenitor IAVs based on the literature (26,27).
We downloaded nucleotide sequences of the vi-
ruses’ HA1, the main target of neutralizing antibod-
ies, from Genbank and translated these to amino ac-
ids. We used the MUSCLE algorithm for sequence 
alignment and the Jones-Taylor-Thornton model and 
nearest-neighbor-interchange heuristic method to 
construct maximum-likelihood trees in MEGA7 (28). 
We determined the percent of amino acid homology 
between test viruses and numbers of identical amino 
acids in presumed antigenic sites (29) with MEGA7 
and R version 3.2.2 (30).
We obtained North American swIAVs and cor-
responding swine serum from the U.S. Department 
 
Table 1. Swine and human H1 influenza A virus strains used in hemagglutination inhibition and virus neutralization assays of human 
serum samples, Belgium* 
Virus strain Abbreviation Subtype Colloquial name H1 H1 clade 
H1 GenBank 
Accession no. 
A/swine/Gent/28/2010 swG10 H1N1 European avian-like 1C.2.1 KP406525 
A/swine/Hong Kong/2032/2011 swHK11 H1N1 Asian avian-like 1C.2.3 KM028543 
A/Taiwan/1/86 TW86 H1N1 Human seasonal 1B.1-like X17224 
A/swine/Gent/26/2012 swG12 H1N2 European human-like 1B.1.2.1 KP406526 
A/New Caledonia/20/99 NC99 H1N1 Human seasonal 1B.2-like DQ508857 
A/swine/Alabama/A01104091/2016 swAL16 H1N2 North American human-like δ1a 1B.2.2.1 KX247675 
A/swine/Illinois/A01047020/2010 swIL10 H1N2 North American human-like δ1b 1B.2.2.2 JQ756323 
A/swine/Oklahoma/A01290605/2013 swOK13 H1N1 North American human-like δ1b 1B.2.2.2 KF791395 
A/Brisbane/59/2007 BR07 H1N1 Human seasonal 1B.2-like CY058487 
A/swine/Ohio/511445/2007 swOH07 H1N1 North American classical swine γ 1A.3.3.3 EU604689 
A/California/04/2009 CA09 pH1N1 2009 pandemic 1A.3.3.2 FJ966082 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first.   
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of Agriculture-Agricultural Research Service. We 
obtained human seasonal IAVs and corresponding 
ferret serum from Francis Crick Institute (London, 
UK), and Asian swIAV from Hong Kong University 
(Hong Kong). We antigenically characterized test vi-
ruses in cross-HI and cross-VN assays with postvac-
cination swine serum for swIAVs or postinfection 
ferret serum for human seasonal IAVs. Because se-
rum against A/Brisbane/59/2007 was not available, 
we used ferret serum against A/Egypt/10/2007 
instead; the HA sequence is identical in both. We 
propagated viruses in MDCK cells; all passages 
were <6. We calculated antigenic distances from 
HI and VN titers as described previously (31) and 
converted these into antigenic dendrograms by us-
ing the neighbor-joining method in MEGA7. One 
antigenic unit represents a 2-fold difference in HI 
or VN titer.
Serologic Assays
We tested individual samples in HI assays and 
pooled samples per birth year in VN assays for anti-
bodies against each test virus. Both assays were per-
formed according to standard procedures (32,33). 
We expressed antibody titers for HI as the recipro-
cal of the highest serum dilution showing complete 
hemagglutination inhibition of 4 hemagglutinating 
units of virus or, for VN, 50% neutralization of 100 
TCID50 (50% tissue culture infective doses) of virus. 
The starting dilution was 1:20, and we considered a 
titer of ≥40 positive.
Statistical Analyses
We calculated geometric mean titers (GMTs) and 
95% CIs for HI and VN antibody titers of samples 
from each birth decade against each test virus by us-
ing log2-transformed data. Samples with a titer <20 
were assigned a titer of 10. For non-stratified data, we 
calculated Spearman correlation coefficients (CCs) 
between HI titers or between VN titers against dif-
ferent viruses. We used Kruskal-Wallis and Mann-
Whitney U tests to compare antibody titers between 
age groups for a certain virus or between viruses for 
a certain age group. We used Fisher exact test to com-
pare proportions of positive samples. For all statisti-
cal tests, we applied Bonferroni adjustment of the p 
values and we considered corrected p values of <0.05 
statistically significant. We performed all analyses by 
using R version 3.2.2.
Results
Genetic and Antigenic Relatedness Between  
Test Viruses
We tested samples for antibodies against 11 IAVs 
from the classical swine 1A, human seasonal 1B, or 
Eurasian avian 1C lineage. HA1 aa sequence homol-
ogy between viruses of different lineages was <75% 
with 19–35/50 identical amino acids in presumed 
antigenic sites. Classical swine and avian-like IAVs 
were phylogenetically most closely related (Figure 1, 
panel A; Table 2). Within-lineage HA1 aa homology 
was 82%–97%, with 36–49 identical amino acids in 
Figure 1. Epidemiologic, phylogenetic, and antigenic relationship between influenza A test viruses from classical swine lineage 1A, 
human seasonal lineage 1B, and Eurasian avian lineage 1C. A) Schematic representation of the H1 IAV epidemiology and maximum-
likelihood neighbor-joining phylogenetic tree of the HA1 of representative test viruses. B) Antigenic dendrogram based on antigenic 
distances in cross-hemagglutination inhibition assays. C) Antigenic dendrogram based on antigenic distances in cross-virus neutralization 
assays. IAV, influenza A virus.
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antigenic sites. Human-like swIAVs and their pre-
sumed human seasonal progenitor IAV shared 90%–
94% aa in the HA1 and 36–42 aa in antigenic sites.
Antigenic dendrograms based on cross-HI 
and cross-VN assays showed similar trends to the 
phylogenetic tree, except for swOK13 (Tables 3–5; 
Figure 1). This North American human-like δ1b 
swIAV (1B.2.2.2) clustered separately from other 
IAVs of its lineage, including its presumed human 
ancestor, NC99.
Seroreactivity against Human Seasonal IAVs
We tested human serum samples against human sea-
sonal IAVs related to 1B swIAVs from 1986 (TW86), 
1999 (NC99), and 2007 (BR07) to evaluate a person’s 
potential exposure to or vaccination with these IAVs. 
Overall, 39% were seropositive for TW86, 31% for 
NC99, and 22% for BR07 in HI and 48% were sero-
positive for TW86, 51% for NC99, and 29% for BR07 
in VN (Figures 2, 3). Seroprevalences and GMTs 
against TW86 were highest for persons born dur-
ing 1977–1986 and lowest for the 2 youngest groups, 
those born during 1997–2017 (Tables 6, 7). For NC99 
and BR07, HI responses were highest for those born 
during 1987–1996, and VN responses were highest for 
those born during 1937–1946 (NC99 only) and 1997–
2006. Persons born during 2007–2017 had minimal re-
sponses. Antibody responses against human seasonal 
IAVs were related to birth year and the year of virus 
isolation, with peak responses in persons born right 
before the virus circulated and lowest responses in 
persons born afterwards.
 
Table 2. Percentage amino acid homology (lower left) and number of identical amino acids out of 50 aa in presumed antigenic sites 
(upper right) (28) between hemagglutinin 1 of human and swine H1 influenza A viruses used as test viruses in hemagglutination 






























swG10 – 49  22 19 23 24 23 23 23  32 34 
swHK11 96.0 –  23 20 23 25 23 23 23  33 35 
TW86 73.4 72.2  – 41 41 38 36 32 38  23 23 
swG12 69.1 68.5  89.6 – 35 33 33 32 32  21 22 
NC99 73.3 72.1  93.9 85.9 – 42 42 36 47  24 24 
swAL16 71.5 71.2  89.3 81.6 91.4 – 45 40 40  23 27 
swIL10 72.1 71.5  89.6 83.4 94.2 92.9 – 43 42  23 25 
swOK13 72.0 72.0  86.8 81.8 90.2 89.2 94.8 – 36  20 24 
BR07 72.7 71.5  90.8 83.7 96.9 89.9 92.3 88.6 –  24 24 
swOH07 74.0 74.3  74.3 71.6 73.0 72.4 71.8 70.5 73.6  – 44 
CA09 73.4 72.5  73.4 70.9 72.4 73.9 72.1 71.1 72.4  90.8 – 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first. 
Complete isolate names are provided in Table 1. IAV, influenza A virus; N. Am., North America; –, not applicable. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
 
 































swG10 640 40  <20 <20 <20 <20 <20 <20 <20  <20 20 
swHK11 640 640  <20 <20 <20 <20 <20 <20 <20  40 40 
TW86 <20 <20  1,280 160 20 <20 <20 <20 <20  <20 <20 
swG12 20 <20  160 1,280 20 20 <20 <20 <20  <20 <20 
NC99 <20 <20  <20 <20 640 <20 <20 <20 80  <20 <20 
swAL16 <20 <20  <20 <20 160 320 20 <20 20  <20 <20 
swIL10 <20 <20  <20 <20 40 40 320 <20 160  <20 <20 
swOK13 <20 <20  <20 <20 <20 <20 <20 640 <20  <20 <20 
BR07 <20 <20  <20 <20 40 <20 <20 <20 1,280  <20 <20 
swOH07 20 40  <20 <20 <20 <20 <20 20 <20  1,280 640 
CA09 20 20  <20 <20 <20 <20 <20 <20 <20  160 1,280 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first. 
Complete isolate names are provided in Table 1. Bold indicates HI titer against the homologous virus. IAV, influenza A virus; HI, hemagglutination 
inhibition; N. Am., North America. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
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Seroreactivity against swIAVs of the Eurasian  
Avian Lineage 1C
The major avian-origin swIAV clades are European 
avian-like 1C.2.1, represented by swG10, and Asian 
avian-like 1C.2.3, represented by swHK11. For swG10, 
10% of all samples tested positive in HI and 7% in VN 
(Figures 2, 3). Seroprevalence was <20% and GMTs 
were <20 for all age groups except the oldest, those 
born during 1920–1926, with 40% seropositive in HI 
and GMTs for HI and VN of 24 (Tables 6, 7).
For swHK11, overall seroprevalence was 25% in 
HI and 34% in VN. As for  swG10, responses against 
swHK11 were highest for those born during 1920–
1926; 52% in HI, 72% in VN, and GMTs ≥38. Responses 
were minimal in both HI and VN for persons born dur-
ing 1947–1956; 11% in HI, 10% in VN, and GMTs <20.
Seroreactivity against swIAVs of the Human  
Seasonal Lineage 1B
European human-like swIAV swG12 (1B.1.2.1) rep-
resents the human-like H1 swIAV clade circulating 
in Belgium, and TW86 was selected as its presumed 
human ancestor virus. At least half of all samples 
tested positive for swG12, 50% in HI and 59% in VN 
(Figures 2, 3). We noted statistically significant dif-
ferences in seroprevalences and GMTs, which were 
higher (62% in HI and 74% in VN; GMTs ≥44) in per-
sons born before 1996 than in persons born during 
1997–2017 (5% in HI and in VN; GMTs <20; p<0.001) 
(Tables 6, 7). GMTs peaked (≥87) in HI in those born 
during 1977–1986 and in VN for those born during 
1967–1976. Results for swG12 were similar to those 
for its presumed human ancestor virus, TW86.
 































swG10 1,920 40  <20 <20 <20 <20 <20 <20 <20  <20 20 
swHK11 640 640  <20 <20 30 <20 <20 <20 40  60 80 
TW86 <20 <20  1,920 320 40 <20 <20 <20 <20  <20 30 
swG12 <20 <20  120 3,840 20 20 <20 <20 <20  <20 <20 
NC99 <20 <20  <20 <20 1,280 30 80 <20 160  <20 <20 
swAL16 <20 <20  <20 <20 640 960 80 <20 160  <20 <20 
swIL10 <20 <20  <20 <20 120 160 3,840 <20 320  <20 <20 
swOK13 <20 <20  <20 <20 <20 <20 20 1,280 <20  <20 20 
BR07 <20 <20  <20 <20 240 <20 60 <20 2,560  <20 <20 
swOH07 <20 60  <20 20 20 <20 <20 <20 120  1,920 960 
CA09 <20 <20  <20 <20 <20 <20 <20 <20 <20  160 3,840 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first. 
Complete isolate names are provided in Table 1. Bold indicates VN titer against the homologous virus IAV, influenza A virus; VN, virus neutralization; N. 
Am., North America. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
 
 
Table 5. Antigenic distance in units between human and swine H1 IAVs in cross-hemagglutination inhibition assays (upper right) and 































swG10 – 1.67  4.96 4.67 4.49 4.15 4.30 4.24 4.69  4.41 4.23 
swHK11 1.93 –  5.20 5.03 4.77 4.53 4.69 4.50 4.92  3.75 3.82 
TW86 4.84 4.98  – 2.12 4.77 4.54 4.79 4.80 5.14  5.63 5.54 
swG12 4.87 5.09  2.31 – 4.77 4.33 4.74 4.77 5.14  5.65 5.53 
NC99 4.65 4.37  4.72 4.85 – 2.62 3.04 4.35 2.74  5.19 5.08 
swAL16 4.62 4.53  4.79 4.71 1.75 – 2.65 3.99 3.67  4.91 4.75 
swIL10 4.95 4.93  5.27 5.19 2.50 2.29 – 4.11 2.75  5.09 4.92 
swOK13 4.34 4.44  4.79 4.83 4.47 4.44 4.63 – 4.56  4.65 4.81 
BR07 4.77 4.36  4.97 5.06 1.91 2.75 2.75 4.63 –  5.35 5.26 
swOH07 4.65 3.48  5.07 5.21 4.71 4.80 5.12 4.73 4.44  – 1.43 
CA09 4.59 3.91  4.89 5.28 5.09 5.01 5.33 4.53 5.17  2.06 – 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first. 
Complete isolate names are provided in Table 1. IAV, influenza A virus; N. Am., North America; – not applicable. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
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North American human-like δ H1 swIAVs (1B.2) 
result from the introduction of a human IAV in the 
early 2000s, and we selected NC99 as their presumed 
human ancestor. For the most prevalent δ1 clade 
(1B.2.2), swAL16 represents subclade δ1a (1B.2.2.1), 
whereas swIL10 and swOK13 represent subclade 
δ1b (1B.2.2.2).
Among samples, 24% tested positive for swAL16 
in HI and 39% in VN (Figures 2, 3). Seroprevalences 
and GMTs were highest in those born during 1987–
1996 in HI (55%; GMT 35) and in those born during 
1947–1956 in VN (70%; GMT 59), but no antibodies 
against swAL16 were detected in the youngest group, 
those born during 2007–2017 (Tables 6, 7). Like for Eu-
ropean human-like virus swG12 (1B.1.2.1), antibody 
responses against North American δ1a virus swAL16 
(1B.2.2.1) resembled those against its presumed hu-
man ancestor virus, NC99.
For the δ1b swIAVs (1B.2.2.2), <10% were seroposi-
tive (swIL10, 10% in HI and VN; swOK13, 5% in HI and 
4% in VN) (Figures 2, 3). We did not see statistically 
significant differences in seroprevalences between the 2 
δ1b swIAVs or between age groups, with following ex-
ceptions. HI-seroprevalence of those born during 1927–
1936 was statistically significantly higher for swIL10 
(13%) than for swOK13 (2%; p<0.04). HI seroprevalence 
for swOK13 of those born during 1977–1986 was statisti-
cally significantly higher (21%) compared with groups 
born during 1927–1936 (2%), 1957–1966 (0), and 2007–
2017 (0; p<0.04). GMTs were <20 in all age groups ex-
cept those born during 1937–1956, who had VN GMTs 
of 22–30 against swIL10 (Tables 6, 7). Unlike the other 2 
human-like swIAVs tested, responses against δ1b swI-
AVs (1B.2.2.2) did not concur with those against the pre-
sumed human ancestor virus NC99. Responses against 
swIL10 and swOK13 were generally statistically signifi-
cantly lower than against NC99 (p<0.05).
Seroreactivity against swIAVs of the Classical  
Swine Lineage 1A
We used swOH07 as reference virus to evaluate anti-
body responses against classical swine virus clade γ 
Figure 2. Number of positive 
human serum samples in the 
hemagglutination inhibition assay 
(titer >40) for each test virus 
compared with the total number 
of samples tested per birth cohort. 
Birth cohorts are represented as 
different colors. During August 
2017–January 2018, a total of 549 
serum samples were collected 
from immunocompetent persons 
in Belgium.
Figure 3. Number of positive 
human serum samples in the 
virus neutralization assay 
(titer >40) for each test virus 
compared with the total number 
of samples per birth cohort. 
Birth cohorts are represented as 
different colors. During August 
2017–January 2018, a total 
of 549 serum samples were 
collected from immunocompetent 
persons in Belgium and pooled 
per year of birth (n = 98).
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(1A.3.3.3) and CA09 as reference virus to evaluate clas-
sical swine virus clade pH1N1 (1A.3.3.2), which derived 
its HA from γ swIAVs. Overall, ≥50% of the samples 
tested positive for swOH07 (50% in HI; 78% in VN) and 
CA09 (54% in HI; 81% in VN), with high seroprevalenc-
es in all age groups (36%–100% in HI; 50%–100% in VN), 
except in those born during 1947–1956 in HI (swOH07, 
17%; CA09, 24%) (Figures 2, 3). HI titers peaked in the 
2 oldest groups, those born during 1920–1936; VN titers 
peaked in the 2 oldest groups and in those born during 
1997–2006 (Tables 6, 7). No statistically significant dif-
ference was noted in responses against classical swine γ 
(1A.3.3.3) and pH1N1 (1A.3.3.2) IAVs.
Correlations Between Antibody Titers against Human 
Seasonal and Swine IAVs
Antibody titers against epidemiologically related 
human and swine IAVs were highly correlated for 
classical swine viruses swOH07 (1A.3.3.3) and CA09 
(1A.3.3.2), European human-like swIAV swG12 
(1B.1.2.1) and human ancestor IAV TW86, North 
American human-like δ1a swIAV swAL16 (1B.2.2.1) 
and human ancestor IAV NC99, and European and 
Asian avian-like swIAVs swG10 (1C.2.1) and swHK11 
(1C.2.3) (CC = 0.68–0.86 in HI; CC = 0.63–0.77 in VN; 
Table 8). Of note, titers against avian-like and classical 
swine IAVs also were strongly correlated (CC = 0.55–
0.68 in HI; CC = 0.49–0.67 in VN). In contrast, CCs were 
low between titers against North American human-like 
δ1b viruses swIL10 and swOK13 (1B.2.2.2) and human 
ancestor virus NC99 (0.42–0.43 in HI; 0.30–0.39 in VN 
[the first value of which is not statistically significant]).
Discussion
Our results show that serum antibody responses 
of immunocompetent persons in Belgium against 
 
Table 6. Geometric mean of hemagglutination inhibition antibody reactivity against different H1 influenza A viruses of humans and 
swine in different age groups of the population, 2017–2018, Belgium* 
Birth year 
range 





















































































































































































































































































































*Values expressed represent geometric mean hemagglutination inhibition titers (95% CI). Eur., Europe; N. Am., North America. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
‡Age at the end of 2017. 
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major H1 swIAV clades depend on the swIAV test-
ed and its relation to human seasonal IAVs and the 
person’s birth year. Overall seroprevalences were 
high (≥50%) for classical swine (1A.3.3.2, 1A.3.3.3) 
and for European human-like (1B.1.2.1) swIAVs, in-
termediate (≥24%) for North American human-like 
δ1a (1B.2.2.1) and Asian avian-like (1C.2.3) swIAVs, 
and low (<10%) for North American human-like δ1b 
(1B.2.2.2) and European avian-like (1C.2.1) swIAVs. 
Our results are consistent with previous studies that 
aimed to compare antibody responses in nonswine 
workers with those in persons with frequent swine 
contact (7,20–25), although those studies examined 
only a limited number of swIAV clades or sam-
ples. Overall, most previous studies showed lower 
seroprevalences for Asian avian-like (2%–10%) and 
European avian-like (0–5%) swIAVs in the general 
population or in nonswine workers (13,20,22–24). 
A 2010 study in the United Kingdom also found 
a lower seroprevalence of 11% for a European 
human-like (1B.1.2.1) swIAV (24). The major dif-
ference between our study and studies conducted 
before or during the 2009 pandemic is the lower 
seroprevalence of 3%–15% for classical swine IAVs 
in previous studies (13,20,22–24). The circulation of 
pH1N1 viruses (1A.3.3.2) likely contributes to in-
creased seroprevalence rates against these related 
classical swine IAVs. In our study, the oldest group, 
those born during 1920–1926 who are 91–97 years 
of age, had the highest antibody responses against 
H1 swIAVs of classical swine (1A.3.3) and avian-
like (1C.2) lineages, for which antibody titers were 
correlated (13,20,21). Responses against human 
seasonal IAVs and related European and North 
American δ1a human-like H1 swIAVs (1B) gener-
ally were highest in those born during 1977–1996, 
who are 21–40 years of age, and lowest in those 
born during 1996–2017, who are 0–20 years of age. 
Responses against North American δ1b human-like 
H1 swIAVs (1B.2.2.2) generally were low across all 
age cohorts.
Antibody responses against past human season-
al IAVs TW86, NC99, and BR07 generally peaked in 
persons born near the time during which the respec-
tive IAV or similar viruses circulated, whereas re-
sponses were low in most persons born after. With-
in an age group, responses generally were highest 
against an antigenic representative of the virus en-
countered first. These findings concur with the the-
ory of antigenic seniority: humans are expected to 
 
Table 7. Geometric mean of virus neutralization titers and antibody reactivity against different human and swine H1 influenza A viruses 







































































































































































































































































































*Values expressed represent geometric mean virus neutralization titers of pooled serum samples per birth year (95% CI).  
N. Am., North America; Boldface indicates geometric mean VN titers of pooled serum samples per birth year. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
‡Age at the end of 2017. 
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have antibodies against human seasonal IAVs that 
circulated after their birth, with highest responses 
against the virus encountered first. Antigenic senior-
ity likely occurs because of periodic boosting of these 
antibodies by subsequent exposures to related hu-
man seasonal IAVs (4,34,35). Antibody titers against 
European human-like swIAV swG12 (1B.1.2.1) and 
North American human-like δ1a swIAV swAL16 
(1B.2.2.1) concur with those against their respective 
human ancestor viruses TW86 and NC99 because of 
close antigenic relationship to their ancestor IAV. 
Overall high seroprevalences against pH1N1 virus 
CA09 (1A.3.3.2) and antigenically closely related 
classical swine γ virus swOH07 (1A.3.3.3) can be 
explained by recent exposure to currently circulat-
ing pH1N1 viruses. Because the oldest persons were 
born during 1920–1936, when human IAVs closely 
related to the 1918 pandemic virus, the ancestor of 
classical swine IAVs, circulated, they could have 
had cross-reactive antibodies against classical swine 
IAVs before 2009. These antibodies might have been 
boosted by later exposure to pH1N1 viruses, which 
might account for the high responses in this group 
(6,7). Consistent with results for serum samples 
collected after pH1N1 virus infection in a previ-
ous study (21), cross-reactivity was higher against 
the Asian than against the European avian-like H1 
swIAV, which differ by only 1 aa in antigenic sites 
(Table 2). Whether this single amino acid mutation 
is the reason for the difference in seroprevalence is 
still unknown (36,37).
European human-like (1B.1.2.1) and North 
American human-like δ1a (1B.2.2.1) H1 swIAVs 
are antigenically more closely related to their 
human ancestor than North American human-like 
δ1b (1B.2.2.2) H1 swIAVs (Figure 1; Tables 3, 4). 
North American human-like δ H1 swIAVs (1B.2) 
have been shown to drift 4 times faster than Eu-
ropean human-like H1 swIAVs (1B.1). Increased 
antigenic diversity of the former since 2008 has 
led to the emergence of swIAVs that are antigeni-
cally distinct from the human precursors, mainly 
within the δ1b subclade (3,27). This evolution can 
explain the recognition of selected European hu-
man-like and North American human-like δ1a but 
not North American human-like δ1b H1 swIAVs 
by human serum samples. Because the human an-
cestor IAVs no longer circulate in humans, swine 
can be considered a reservoir for old human IAVs. 
Seroprevalences for European human-like and 
North American human-like δ1a H1 swIAVs are 
expected to decrease over time because the young-
est age groups were never exposed to these human 
IAVs. On the basis of our results, we estimate that it 
could take <80 years for the population to become 
fully susceptible.
Seroprevalences of immunocompetent persons 
in Belgium for swIAVs representing major H1 swI-
AV clades suggest that North American human-like 
δ1b (1B.2.2.2) and European avian-like (1C.2.1) H1 
swIAVs currently pose the highest risk to public 
health. North American human-like δ1b (1B.2.2.2) 
swIAVs rapidly drifted away from its human an-
cestor, whereas European avian-like (1C.2.1) swIA-
Vs never circulated in humans. Seroprevalences of 
<10% for these viruses are comparable to 2%–19% 
against the pH1N1 virus right before the pandemic 
(7). Our results suggest that the risk of reintroduction 
 
Table 8. Spearman correlation coefficients between hemagglutination inhibition antibody titers against human and swine H1 influenza 






























swG10 – 0.68  NS 0.16 0.19 0.19 NS 0.26 0.18  0.56 0.55 
swHK11 0.63 –  0.24 0.26 0.32 0.31 0.23 0.43 0.30  0.68 0.63 
TW86 NS NS  – 0.84 0.52 0.43 0.21 0.35 0.35  0.25 0.26 
swG12 NS NS  0.77 – 0.42 0.41 0.23 0.37 0.28  0.30 0.27 
NC99 NS NS  0.46 0.37 – 0.69 0.42 0.43 0.75  0.36 0.36 
swAL16 NS NS  NS NS 0.71 – 0.53 0.38 0.58  0.43 0.39 
swIL10 NS NS  NS 0.37 0.39 0.52 – 0.37 0.45  0.30 0.26 
swOK13 NS NS  NS NS NS NS 0.35 – 0.39  0.33 0.34 
BR07 NS NS  NS NS 0.76 0.57 NS NS –  0.30 0.31 
swOH07 0.55 0.67  NS NS NS NS NS NS NS  – 0.86 
CA09 0.49 0.62  NS NS NS NS NS NS NS  0.74 – 
*Viruses are ordered chronologically according to the year of circulation of the selected human test viruses TW86, NC99, BR07, and CA09; horizontal 
rules within table represent grouping of epidemiologically related human and swine influenza A viruses, with the oldest (ancestor) virus mentioned first. 
Complete isolate names are provided in Table 1. N. Am., North America; NS, not significant; –, not applicable. 
†Human IAV that no longer circulates; TW86 is the presumed human precursor for human-like H1 swine IAVs in Europe; NC99 is the presumed human 
precursor for human-like H1 swine IAVs in North America; BR07 is a human seasonal IAV that circulated right before the influenza A(H1N1)pdm09 virus; 
the influenza A(H1N1)pdm09 virus, represented by CA09, is circulating in both humans and swine worldwide. 
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of these H1 swIAVs in the human population might 
be higher than for H3 swIAVs, given that ≥20% of 
persons 0–100 years of age from Luxembourg test-
ed seropositive for representative European and 
North American cluster IV H3 swIAVs in 2010 (19). 
Seroprevalences against the other currently circulat-
ing human-like H1 swIAV clades were higher than 
against 1B.2.2.2 and 1C.2.1, but these viruses, along 
with H3 swIAVs, also keep evolving in swine. As 
they continue to drift away from their human ances-
tor and population immunity wanes with lack of ex-
posure, these viruses might also pose a risk to public 
health soon.
We evaluated human population immunity 
against H1 swIAVs on the basis of serum HI and 
VN antibodies, which are directed against the high-
ly variable head region of the HA. We did not mea-
sure antibodies or T-cell responses against the HA 
stalk, the neuraminidase, or internal viral proteins, 
such as the nucleoprotein. Although these immune 
mechanisms are much less potent than neutraliz-
ing anti-HA antibodies, their targets are more con-
served between IAVs of humans and swine (38–42). 
Therefore, persons with minimal antibody titers in 
our study still might have some degree of immu-
nity and protection against zoonotic infection with 
swIAVs. Furthermore, population immunity is 
only one aspect determining the pandemic poten-
tial of swIAVs (18). Another factor is their ability 
to spread in humans, which is difficult to investi-
gate (43). Our results stress the need for continu-
ous surveillance and characterization of circulating 
swIAVs and frequent monitoring of humans for an-
tibodies against these swIAVs.
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